Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis ; volume:7 ; number:1 ; day:2 ; month:8 ; year:2017 ; pages:1-8 ; date:12.2017
Scientific reports ; 7, Heft 1 (2.8.2017), 1-8, 12.2017
- Urheber
-
ter Veer, Emil
Ngai, Lok Lam
Valkenhoef, Gert van
Mohammad, Nadia Haj
Anderegg, Maarten C. J.
van Oijen, Martijn G. H.
van Laarhoven, Hanneke W. M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-07750-3
- URN
-
urn:nbn:de:101:1-2019102013210108559366
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- ter Veer, Emil
- Ngai, Lok Lam
- Valkenhoef, Gert van
- Mohammad, Nadia Haj
- Anderegg, Maarten C. J.
- van Oijen, Martijn G. H.
- van Laarhoven, Hanneke W. M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biota
Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biota
Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Assessing the risks of capecitabine and its active metabolite 5-fluorouracil to freshwater biota
Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur : a consensus paper
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial